

Santen Announces Status of Repurchase of Own Shares

November 1, 2016, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) announced status of the repurchase of its own shares as stated below. The repurchase was implemented in accordance with Article 156 of the Companies Act (Japan), as applied pursuant to Article 165, paragraph 3.

- | | |
|--|---|
| 1. Class of shares repurchased: | Common shares of Santen |
| 2. Total number of shares repurchased: | 3,717,700 shares |
| 3. Total amount of repurchase: | 5,619,071,259 yen |
| 4. Period of repurchase: | October 3, 2016 to October 31, 2016
(execution date basis) |
| 5. Method of repurchase: | Purchased on the Tokyo Stock Exchange |

(Reference)

1. Details of the resolution at the meeting of the Board of Directors (announced on September 12, 2016)

- | | |
|---|---|
| - Class of shares to be repurchased: | Common shares of Santen |
| - Total number of shares to be repurchased: | Up to 8,284,000 shares (2.0% of issued shares, excluding treasury shares) |
| - Total amount of repurchase: | Up to 13 billion yen |
| - Period of repurchase: | September 13, 2016 to November 30, 2016 |

2. Total Company's own shares repurchased through October 31, 2016, pursuant to the above Board resolution

- | | |
|---------------------------------------|-------------------|
| - Total number of shares repurchased: | 5,149,800 shares |
| - Total amount of repurchase: | 7,683,449,966 yen |

About Santen

As a specialty company dedicated to the ophthalmic field, Santen carries out research, development, sales, and marketing of pharmaceuticals. Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals and sells products in over 50 countries. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs. For more details, please see Santen's website (www.santen.com).

Santen Forward-looking Statements

Information provided in this press release contains forward-looking statements. The achievement of these forecasts is subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial conditions are subject to the effects of changes in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.

Contact**Christopher Hohman**

General Manager

Corporate Communications Group

Santen Pharmaceutical Co., Ltd.

E-mail: ir@santen.co.jp

Tel: +81-6-4802-9360